---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022484"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:00:12.348724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vistagen expands PH80 global patent portfolio with new migraine treatment patents in four countries

## Summary
- New patents for PH80 migraine treatment issued/allowed in Australia, Hong Kong, Japan, and Mexico.
- All new patents expected to be in effect until 2040, subject to possible term extensions.
- PH80 is a non-systemic, hormone-free investigational pherine nasal spray for menopausal hot flashes and other conditions.
- Patents complement previously granted U.S. Patent No. 11,419,881 and EPO Patent No. 3955933 for migraine.

## SEC filing metadata
- accession: 0001437749-24-022484
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/0001437749-24-022484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924022484/vtgn20240710_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022484
- JSON: https://secwatch.observer/filing/0001437749-24-022484.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.